Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline
Merck, also known as MSD outside the United States and Canada, is set to unveil…
What is CAR-T cell therapy?
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a revolutionary form ofimmunotherapy that has gained significant attention in recent years for its remarkable success intreating certain types of cancer, particularly blood cancers. This cutting-edge treatment involvesharnessing the power of the patient’s immune system to target and destroy cancer cells, offeringnew hope for…
Crucible Therapeutics, a spinout of the University of Sheffield in England, has secured £5million (approximately $6.1 million) in funding to advance its development of genetherapies
Gene therapies will be targeting neurodegenerative disorders associated with C9orf72gene mutations. The financing comes from investment firm Northern Gritstone and Europeanstartup studio Argobio Studio. These funds will support preclinical development andmanufacturing efforts aimed at preparing Crucible Therapeutics for its initial clinical trial. Thecompany’s focus is on addressing conditions such as motor neuron disease (MND), amyotrophiclateral…
Navigate BioPharma, a subsidiary of Novartis, has recently announced a strategic collaboration with Becton Dickinson (BD)
Collaboration aimed at advancing the development and commercialization of companion diagnostics and clinical decision-making tools utilizing flow cytometry technology. This partnership represents a significant step in the field of precisionmedicine and holds the potential to enhance the efficiency and accuracy of patient treatmentmatching.Through this collaborative effort, BD and Navigate BioPharma aim to offer comprehensivesolutions for…
AstraZeneca and Daiichi’s breast cancer drug Shows Promise in Phase III BreastCancer Trial
AstraZeneca’s Dato-DXd, an antibody drug conjugate, has shown promising results in a Phase IIIbreast cancer trial, known as TROPION-Breast01, conducted to assess its effectiveness inpatients with advanced HR-positive, HER2-low or -negative breast cancer. The trial revealed asignificant and clinically meaningful improvement in progression-free survival when comparedto chemotherapy chosen by investigators. AstraZeneca intends to share these…
Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline
Merck, also known as MSD outside the United States and Canada, is set to unveil a wealth of data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, spanning various oncology medicines and pipeline candidates targeting over 25 types of cancer. These presentations highlight Merck’s ongoing commitment to advancing cancer research…
Diasorin Secures FDA 510(k) Clearance for Enhanced Respiratory Panel
Diasorin recently announced that the US Food and Drug Administration has granted 510(k) marketing clearance for their updated molecular respiratory panel, now including SARS-CoV-2 detection. The NxTag Respiratory Pathogen Panel v2, based in Saluggia, Italy, utilizes multiplex PCR to identify 19 viral and two bacterial targets in nasopharyngeal swab samples from patients displaying respiratory symptoms….
Seegene and Springer Nature Forge Strategic Partnership
Seegene , a leading South Korean PCR molecular diagnostics company, has entered a strategic alliance with Springer Nature, publisher of the prestigious journal, Nature. Aligned in their mission to advance scientific discovery and combat diseases, this alliance aims to accelerate PCR diagnostic testing across various disease areas. The collaboration leverages the expertise of both parties…
Radiation oncology in the era of Precision Medicine
Radiation therapy utilizes high doses of ionizing or particulate radiation to kill cancer cells. It is an integral component of multimodality cancer care. However, the challenge lies in delivering it precisely to the target while sparing surrounding healthy tissues. Technological advancements have revolutionised radiation therapy planning and delivery leaps and bounds. Especially incorporation of axial…
U.S. FDA Grants Approval to Bristol Myers Squibb’s Breyanzi CAR T Cell Therapy for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CAR T cell therapy targeting CD19, to treat adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone two or more prior lines of systemic therapy. This approval, based on response rate…
Indian Council of Medical Research (ICMR) Issues Protocol for Evaluating TB Detection Technologies: A Generic Concordance Study
The Indian Council of Medical Research (ICMR) has issued a Generic Concordance Study Protocol aimed at evaluating tuberculosis (TB) detection technologies. This protocol seeks to establish the agreement between two iterations of an approved molecular TB detection technology. Through a cross-sectional approach, it aims to ascertain the concordance in identifying both TB and drug-resistant TB…
Bayer Initiates Phase I Trial of Innovative Targeted Radionuclide Therapy, 225Ac-PSMA-Trillium, in Advanced Metastatic Prostate Cancer
Bayer has announced the commencement of dosing in a Phase I clinical study for 225Ac-PSMA-Trillium (BAY 3563254), a novel targeted alpha therapy aimed at treating advanced metastatic castration-resistant prostate cancer (mCRPC). This investigational candidate, utilizing actinium-225, features a unique PSMA-targeting small molecule with a customized albumin-binding component. The study, identified as NCT06217822, will focus on…
Triumph Over SMA: A Story of Collective Effort and Medical Breakthrough
A 23-month-old boy named Hridyansh, afflicted with spinal muscular atrophy (SMA), underwent groundbreaking gene therapy at J K Lon Hospital, financed through innovative means. The procedure, costing Rs 17.5 crore, was facilitated by a remarkable crowdfunding effort, spearheaded by Hridyansh’s determined parents, who garnered support from various quarters including the police department and local politicians….
Leading Visionary in the field of Precision Oncology
Step into the world of Dr (Prof) Amrit Kaler, MD as we embark on a journey through her remarkable career, passions, and vision. 1) What do you believe are the key qualities or skills that have contributed to your success in both your professional and leadership roles? In the current complex scenario, there are many…
Triomics Raises $15M to Automate Oncology Workflows with GenAI-Powered Platform
Triomics, a company spearheaded by co-founders Sarim Khan and Hrituraj Singh, has recently secured $15 million in funding to revolutionize cancer care workflows. Their innovative approach combines generative AI and specialized software to address the cumbersome process of manually sifting through patient health records in oncology settings. The company’s flagship product, OncoLLM™, is a specialized…
